Tagged with ess

LatAm Florencia Davel, head of LatAm operations for Bristol Myers Squibb (BMS) looks back on a successful four years in position, shaping the regional organisation into a true biopharma player in line with a global strategy shift. Davel also casts her eye over the market access scenario in LatAm, why BMS…

UK Pricing and market access have become increasingly hot topics in recent years, as healthcare systems across the world attempt to balance their own financial sustainability with securing the latest medical innovations and the premium costs associated with them. Health inequity and access disparities exist between both rich and developing countries,…

Vietnam Despite a decline in pharmaceutical sales during the COVID-19 pandemic, Vietnam is among the 17 countries with the most rapidly growing pharmaceutical industries in the world, as reported by nganhduoc.vn in its 2022 pharma industry forecast. With a market value of some USD 10 billion in 2020, according to another…

Egypt PhRMA’s Middle East & Africa (MEA) group appoints a ‘champion’ for each of its markets to bring the priorities of that country to the agenda of the MEA executive committee. Egypt’s champion is Amgen and – as the company’s MEA lead Mohammed Nasser describes – there is much to be…

Brazil Rolf Hoenger describes how Roche is driving access and awareness for innovative medicines in Latin America and weighs in on a number of important topics, from regulatory harmonisation in the region to digitalisation, clinical trials, Roche’s ongoing global transformation, and how inter-industry collaboration can foster true progress in healthcare.  …

Brazil After a successful international career, Andre Vivan da Silva recently returned to his native Brazil to become GSK’s country manager. He explains the importance of vaccination, in Brazil, and HIV in a country where GSK’s products treat at least half of its HIV patients. He also speaks about the company’s…

Asia-Pacific Through compassionate use programs patients suffering from critical, life-threatening conditions can access potential life-saving therapeutic options which have not been formally approved by the responsible health authority in an ethical and regulated way. ChongXiang Tan, Fengyun (Vicky) Han and Annetta C. Beauregard of Janssen Pharmaceutical Companies of Johnson & Johnson…

Egypt Back in June 2022, Pfizer signed a memorandum of understanding (MoU) with the Egyptian Ministry of Health (MoH) to transfer the technology for producing its pneumococcal vaccine. The fifth highest selling drug in the world in 2020, Prevnar 13 is on the World Health Organization (WHO)’s list for use in routine immunisations given…

Egypt Pfizer’s general manager for Egypt, Ahmed El-Shazly, comments on his return to Egypt after 19 years away, the significant opportunities ahead for the affiliate as it looks to find its place within the country’s healthcare transformation, and the noteworthy MoU signed with the government to potentially localise the production of…

Americas Latin America (LatAm) Area Lead for Astellas Sandra Ramirez outlines the Japanese company’s presence in the region, its efforts to partner with local stakeholders to improve patient access, and the consolidation of its operations in the priority market of Mexico.   LatAm as a region offers many opportunities for innovation.…

Spain Over the course of 2022, PharmaBoardroom spoke to over 50 leading stakeholders in the Spanish healthcare and life sciences, from top Spanish scientists to regional ministers of health, multinational affiliate managers, and the heads of some of the country’s leading domestic firms. These interviewees’ insights are catalogued in the downloadable…

Singapore On World Heart Day 2022 Iris Zemzoum of Novartis Asia Pacific, Middle East & Africa (APMA) outlines the devastating impact of cardiovascular disease (CVD) as well as Novartis’ multipronged approach to overcoming healthcare disparities across a diverse region that is home to half the world’s population. Speaking at the outset…